The FDA has recently admitted there is now major concern over another Pfizer product. It is now slapping a warning on a class of anti-inflammatory treatments called JAK inhibitors. “The U.S. health regulator has added its strictest warning to the labels of drugs from Pfizer, Eli Lilly and AbbVie belonging to a class of anti-inflammatory treatments called JAK inhibitors, citing risk of serious health issues and death in patients 50 and over,” Reuters reported on Friday, citing the drug manufacturers. “The addition of the warning on the labels follows the agency’s review of Pfizer’s Xeljanz after initial results from a…
Just In - Classified
Comments